|N-((1-烯丙基吡咯烷-2-基)甲基)-2,3-二甲氧基-5-氨基磺酰基苯甲酰胺|CsnPharm

CAS No.: 66644-81-3

Veralipride/维拉必利 Catalog No. CSN21891

Synonyms: (±)-Veralipride;LIR166;LIR-1660

Veralipride is an antagonist of D2 receptor. It is used for the treatment of menopausal symptoms.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Veralipride is an anti-dopaminergic agent that relieves hot flushes and putatively also modulates serotonergic neurons. Women treated with veralipride for relief of menopausal symptoms show a decrease in serum levels of serotonin precursors, suggesting that the brain serotonergic system may be involved in the pathogenesis of postmenopausal vasomotor symptoms^[1]. Veralipride, an antidopaminergic drug commonly prescribed to counteract postmenopausal symptoms, may cause reversible parkinsonism^[2]. Veralipride administration (100 mg/day for 30 days) induced a significant reduction in vasomotor symptoms and was more effective than placebo. Treatment was followed by the expected increase in plasma prolactin levels and by a significant decrease in mean plasma LH. A significant reduction was observed in objectively recorded hot flushes after Veralipride treatment, whereas there was no significant change in the characteristics of LH pulsatility^[3]. The combined raloxifene-veralipride treatment, both every other day and every other month, led to a significant improvement in bone density and was effective in hot flushes and other menopause-associated symptoms^[4].
参考文献

[1] Carretti N, Florio P, Reis FM, Comai S, Bertazzo A, Petraglia F. Reduction of serum serotonin precursors after veralipride treatment for postmenopausal hot flushes. Climacteric. 2010;13(2):141‐146
[2] Franchignoni FP, Tesio L. Sindrome parkinsoniana indotta da veralipride [Parkinson syndrome induced by veralipride]. Minerva Ginecol. 1995;47(6):277‐279
[3] Melis GB, Gambacciani M, Cagnacci A, Paoletti AM, Mais V, Fioretti P. Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women. Obstet Gynecol. 1988;72(5):688‐692
[4] Morgante G, Farina M, Cianci A, La Marca A, Petraglia F, De Leo V. Veralipride administered in combination with raloxifene decreases hot flushes and improves bone density in early postmenopausal women. Gynecol Endocrinol. 2004;18(4):194‐198

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.6078 mL
- 13.0391 mL
- 26.0782 mL
- 5 mM
- 0.5216 mL
- 2.6078 mL
- 5.2156 mL
- 10 mM
- 0.2608 mL
- 1.3039 mL
- 2.6078 mL

技术信息

CAS号

66644-81-3

储存条件

粉末: Inert atmosphere,2-8°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C17H25N3O5S

运输

蓝冰

分子量

383.46

别名

(±)-Veralipride;LIR166;LIR-1660;Agreal;Agradil

溶解度

DMSO	98.0 mg/mL (255.6 mM)

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

Veralipride/维拉必利 Catalog No. CSN21891

靶点选择性

请登录您的专属账户

确认信息